Terns Pharmaceuticals Inc [TERN] stock is trading at $40.23, up 37.02%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TERN shares have gain 46.13% over the last week, with a monthly amount glided 120.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Terns Pharmaceuticals Inc [NASDAQ: TERN] stock has seen the most recent analyst activity on November 04, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, William Blair upgraded its rating to Outperform on November 03, 2025. On October 15, 2025, Truist initiated with a Buy rating and assigned a price target of $20 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $15 on September 17, 2025. In a note dated October 31, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $82 on this stock.
Terns Pharmaceuticals Inc [TERN] stock has fluctuated between $1.87 and $30.25 over the past year. Currently, Wall Street analysts expect the stock to reach $30.13 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $40.23 at the most recent close of the market. An investor can expect a potential drop of -25.11% based on the average TERN price forecast.
Analyzing the TERN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.27 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.90 points at the first support level, and at 23.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.78, and for the 2nd resistance point, it is at 53.33.
Ratios To Look Out For
For context, Terns Pharmaceuticals Inc’s Current Ratio is 19.52. As well, the Quick Ratio is 19.52, while the Cash Ratio is 11.3.
Transactions by insiders
Recent insider trading involved Quigley Jill M., Director, that happened on Nov 04 ’25 when 24520.0 shares were sold. Director, JILL QUIGLEY completed a deal on Nov 04 ’25 to buy 24520.0 shares. Meanwhile, Chief Medical Officer Kuriakose Emil sold 944.0 shares on Oct 01 ’25.
